Join us for a virtual KOL Event with Lumos Pharma, featuring Fernando Cassorla, M.D. (University of Chile) and Andrew Dauber, M.D., M.M.Sc. (Children’s National Hospital) who will discuss Lumos Pharma’s investigational drug LUM-201 as potentially the first oral treatment option for Pediatric Growth Hormone Deficiency (PGHD).

The discussion will focus on the recently announced interim results from Lumos Pharma’s Phase 2 OraGrowtH210 Trial and Phase 2 PK/PD OraGrowtH212 Trial evaluating oral LUM-201 for patients with moderate PGHD.

A live Q&A session will follow the formal presentations.